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Abstract 
 
This study aimed to investigate the involvement of adenosine receptors in the 
interaction between paracetamol and caffeine.  Nociception was studied in mice, 
using paracetamol, caffeine, the A2A antagonist, 5-amino-7-(ß-phenylethyl)-2-(8-
furyl)pyrazolo[4,3-e]-1,2,4-triazlol[1,5-c]pyrimidine (SCH58261) or the A2B receptor, 
1-propyl-8-p-sulfophenylxanthine (PSB1115) in the tail immersion and hot plate tests.  
Paracetamol (10-200 mg/kg) was antinociceptive in both tests, but in contrast to 
previous studies caffeine (10 mg/kg) reduced this effect.  SCH58261 (3 mg/kg) was 
antinociceptive in both tests and in its presence paracetamol (50 mg/kg) had no 
further effect.  PSB1115 (10 mg/kg) had little effect alone but potentiated the effect of 
paracetamol (50 mg/kg) in the hot plate test and abolished it in the tail immersion test.  
A2B receptors may therefore be involved in the action of paracetamol in a pathway-
dependent manner.  The results with SCH58261 support the existence of 
pronociceptive A2A receptors, and suggest that A2A antagonists may be effective 
analgesics.   
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1.  Introduction 
 
The adenosine receptor family comprises four subtypes: A1, A2A, A2B and A3 
(Fredholm et al., 2001).  A1 receptors are widely distributed in brain, spinal cord and 
periphery (Fredholm et al., 2001) while A2A receptors are predominantly expressed in 
the periphery (Dunwiddle and Masino, 2001), with only a very restricted central 
expression in the striatum, nucleus accumbens and olfactory tubercle (Jarvis and 
Williams, 1989).  A2B and A3 receptors are widely distributed, but are present at a low 
density in the central nervous system (Feoktistov and Biaggioni, 1997; Rivkees et al., 
2000).  Within the spinal cord adenosine acts to suppress nociceptive signalling, 
mediated via the A1 receptor (DeLander and Hopkins, 1986; Holmgren et al., 1986), 
while in the periphery it has an algogenic activity which may be mediated via an A2 
receptor subtype (McQueen and Ribeiro, 1986; see Sawynok and Yaksh, 1993).  In 
the mouse the location of these receptors are most probably on sensory nerves as there 
is no A2A receptor binding in the spinal cord (Bailey et al., 2002b; Kelly et al., 2004). 
 
Caffeine is a non-specific adenosine antagonist and binds A1 and A2 receptors with 
equal affinity, but does not bind A3 receptors (see Fredholm and Lindstrom, 1999).  It 
is used in combination with non-steroidal anti-inflammatory drugs as an analgesic 
adjuvant (Sawynok and Yaksh, 1993).  In mice, rats and humans caffeine increases 
the antinociceptive effects of paracetamol (Laska et al., 1983; Granados-Soto et al., 
1993; Engelhardt et al., 1997).  When used alone caffeine has been shown to cause 
antinociception in rats and mice (Sawynok et al., 1995; Ghelardini et al., 1997; Abo-
Salem et al., 2004).  
 
It is unclear how caffeine produces its analgesic effect, but it is likely to be via 
adenosine receptor antagonism (Fredholm et al., 1996).  The analgesic adjuvant 
effects of caffeine cannot be due to A1 receptor blockade, as stimulation of A1 
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receptors is known to be antinociceptive (Sawynok and Liu, 2003), genetically 
modified mice lacking the A1 receptor are hyperalgesic (Johansson et al., 2001; Wu et 
al., 2005) and A1  antagonists are pronociceptive (Bastia et al., 2002) or ineffective in 
animal models of pain (Abo-Salem et al., 2004).  Abo-Salem et al (2004) 
demonstrated that novel selective A2B adenosine receptor antagonists produced a 
similar antinociception to caffeine in the hot plate test in mice, raising the possibility 
that part of the action of caffeine might be mediated at the A2B receptor.  Although 
they also reported that adenosine A2A antagonists were not antinociceptive (Abo-
Salem et al., 2004), others have shown antinociceptive effects of A2A antagonists in 
the writhing test (Bastia et al., 2002).  Further, mice deficient in the adenosine A2A 
receptor gene display hypoalgesia (Ledent et al., 1997; Bailey et al., 2002a), raising 
the possibility that both A2 subtypes are involved in nociceptive modulation. 
 
The aim of this study was to compare the effect of caffeine on paracetamol-induced 
antinociception with that of selective antagonists for A2A and A2B receptors.  To 
address this we have studied the effects of paracetamol and caffeine alone and in 
combination in mice, using the hot plate and tail immersion nociceptive tests and also 
the effect of 5-amino-7-(ß-phenylethyl)-2-(8-furyl)pyrazolo[4,3-e]-1,2,4-triazlol[1,5-
c]pyrimidine (SCH58261) and 1-propyl-8-p-sulfophenylxanthine (PSB1115) as 
selective antagonists at A2A and A2B receptors respectively.  In addition we have 
studied the effect of paracetamol and caffeine in mice lacking the adenosine A2A 
receptor gene. 
 
2.  Materials and Methods 
 
2.1. Wild type and adenosine A2A receptor knockout mice 
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The mice used in this study were derived from a breeding colony of adenosine A2A 
receptor knockout mice on a CD-1 background (Ledent et al., 1997) maintained at the 
University of Surrey.  Matings between heterozygote (+/-) animals produced wildtype 
(+/+), heterozygote (+/-) and knockout  (-/-) animals, and the genotype of the animals 
was established at 21 days by tail tipping and DNA amplification using PCR (Ledent 
et al., 1997).  The majority of studies were carried out in the wildtype mice, but in 
some studies with paracetamol and caffeine the knockout mice were used.  After 
weaning, all animals were housed three per cage in an air conditioned unit maintained 
at 20-22°C and 50-60 % humidity and were allowed free access to standard rodent 
chow and water. Lighting was controlled on a twelve-hour cycle, lights on at 07.00 hr.  
Animals were acclimatised to the procedure room for 2 hr prior to testing at 11.00 hr.  
All protocols were carried out in accordance with the Animals (Scientific Procedures) 
Act, 1984 and approved by a local ethical committee.  
 
2.2.  Drug treatment 
 
Mice weighing 25-30 g received paracetamol, caffeine, the A2B antagonist PSB1115  
(Fredholm et al., 1998; Abo-Salem et al., 2004) or the A2A antagonist SCH58261 
(Zocchi et al., 1996; Fredholm et al., 1998; Abo-Salem et al., 2004) alone or in 
combination.  All drugs were injected intraperitoneally (i.p.) in a volume of 8 ml/kg.  
Control groups were given drug vehicle (see Materials) in an equal volume. 
 
2.3.  Tail immersion test 
 
Mice were restrained in a plastic tube with the tail exteriorised and a thermal stimulus 
was applied by immersion of approximately 3 cm of the tip of the tail in a 
thermostatically controlled water-bath kept at a temperature of 53 ± 0.1°C.  Latencies 
for tail withdrawal were recorded for each animal before and after drug administration 
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using a hand-held stopwatch.  A 10 s cut-off time was imposed to avoid tissue 
damage.  
 
2.4.  Hot plate 
 
In a modification of the method of Chen (1951), a 3 mm aluminium plate was placed 
in a thermostatically controlled water-bath kept at a constant temperature of 55 ± 
0.1°C.  The latency for nociceptive response (defined as paw licking or jumping) was 
recorded for each animal before and after drug administration using a hand-held 
stopwatch.  A 30 s cut-off time was imposed to avoid tissue damage.  
 
2.5.  Statistical analysis 
 
Statistical comparison of the drug-treated groups was performed using two-way 
ANOVA (for factors treatment and time) with repeated measures, followed by 
Scheffe’s post hoc test.  P<0.05 was considered significant.  Comparison of basal 
nociceptive latencies between wildtype and knockout animals were performed using 
unpaired Student’s t-test. 
 
2.6.  Materials  
Paracetamol and caffeine were purchased from Sigma-Aldrich (Dorset, UK) and 
dissolved in warmed PBS (Oxoid, Hampshire, UK).  SCH58261 (Sigma-Aldrich, 
Dorset, UK) was dissolved in DMSO (5 mg/ml) which was further diluted in PBS to 
give a final concentration of 15 % DMSO (Fischer Scientific, Loughborough, UK) in 
the drug injection solution.  PSB1115 was dissolved in PBS and was a kind gift from 
Prof. Christa Müller (Bonn University, DE). 
 
 
3.  Results 
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3.1.  Effects of paracetamol and caffeine in the tail immersion test.  
 
The basal response latency of all mice prior to drug administration was 2.23 ± 0.15 s.  
Paracetamol (50–200 mg/kg) administered alone produced significant antinociception 
(P<0.01) at all time points, while 10 mg/kg paracetamol was without effect (Fig. 1A).  
Caffeine (10 mg/kg) administered alone produced a pronociceptive effect which was 
significant at 15 and 30 min (Fig. 1B).  Caffeine (10 mg/kg) abolished the 
antinociceptive effect of paracetamol (50–200 mg/kg) (Fig. 1B,C).  
 
In a further series of experiments caffeine and paracetamol were administered to A2A 
receptor knockout mice, but the basal response latency of all A2A knockout mice prior 
to drug administration was 3.40 ± 0.16 s, significantly higher than the wildtype 
control, (P<0.05).  In these mice paracetamol even at high doses (100-200 mg/kg) and 
caffeine (10 mg/kg) administered alone or in combination failed to increase 
nociceptive response latencies further. 
 
3.2.  The effect of SCH58261 and PSB1115 on the antinociceptive response to 
paracetamol in the tail immersion test.  
 
Paracetamol (50 mg/kg) or the A2A antagonist SCH58261 (3 mg/kg) administered 
alone produced significant antinociception, but in the presence of SCH58261 
paracetamol was unable to induce a further increase in response latency (Fig. 2A).  
The A2B antagonist PSB1115 (10 mg/kg) administered alone did not produce 
significant antinociception, but abolished the effect of paracetamol (50 mg/kg) (Fig. 
2B).  
 
3.3  Effects of paracetamol, caffeine and adenosine receptor antagonists in the hot 
plate test. 
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The basal response latency of all mice prior to drug administration was 8.03 ± 0.39 s.  
Paracetamol administered alone (10–200 mg/kg) produced significant antinociception 
(P<0.01) at 30 min (Fig. 3A).  Caffeine (10 mg/kg) administered alone had no effect 
on nociceptive response latencies (Fig. 3B) but reduced the antinociceptive effect of 
paracetamol (50-200 mg/kg).  This effect was significant (P<0.05) for the highest 
dose (200 mg/kg) of paracetamol (Fig. 3B,C).  
 
In a further series of experiments caffeine and paracetamol were administered to A2A 
receptor knockout mice, but the basal response latency of all knockout mice prior to 
drug administration was 11.35 ± 0.41 s, significantly higher than the wildtype control 
(P<0.05).  Paracetamol even at high doses (100-200 mg/kg) and caffeine (10 mg/kg) 
administered alone or in combination failed to increase nociceptive response latencies 
further. 
 
3.4.  The effect of SCH58261 and PSB1115 on the antinociceptive response to 
paracetamol in the hot plate test. 
 
Paracetamol (50 mg/kg) or the A2A antagonist SCH58261 (3 mg/kg) administered 
alone produced significant antinociception, but in the presence of SCH58261 (3 
mg/kg) paracetamol (50 mg/kg) was unable to increase response latency further (Fig. 
4A).  The A2B antagonist PSB1115 (10 mg/kg) administered alone induced a very 
small antinociceptive response that only achieved significance at 45 min (P<0.05).  
The combination of paracetamol (50 mg/kg) and PSB1115 (10 mg/kg) produced 
antinociception that was significantly greater than paracetamol alone (Fig. 4B). 
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4.  Discussion 
 
Although other studies have reported the effect of high doses of paracetamol (400 
mg/kg) (Pini et al., 1996; Srikiatkhachorn et al., 1999; Sandrini et al., 2001; 
Bonnefont et al., 2003), we did not study doses above 200 mg/kg because of the 
known toxic effects (Tee et al., 1987; Gardner et al., 2002).  Caffeine at a dose of 40 
mg/kg has previously been shown to have an antinociceptive effect in the hot plate 
test when combined with paracetamol (Engelhardt et al., 1997). We also found an 
antinociceptive effect of 40 mg/kg caffeine in the tail immersion and hot plate test 
(data not shown) but doses at this level have questionable relevance to its use as an 
analgesic adjuvant in humans.  As lower doses of caffeine have also been shown to 
exert an antinociceptive effect (Sawynok et al., 1995; Ghelardini et al., 1997; Abo-
Salem et al., 2004), 10 mg/kg caffeine was chosen for the majority of the experiments. 
 
Paracetamol produced an antinociceptive effect in both the tail immersion and the hot 
plate tests at doses between 10-200 mg/kg.  Caffeine (10 mg/kg) administered alone 
in the tail immersion test produced a pronociceptive effect and abolished the 
antinociceptive effect of paracetamol.  In the hot-plate test caffeine alone also did not 
produce an antinociceptive effect, in contrast to the results reported by Abo Salem et 
al (2004). When administered in combination with paracetamol, caffeine again 
inhibited the effects of paracetamol.  In both nociceptive tests therefore caffeine at 10 
mg/kg was not antinociceptive and inhibited rather than enhanced the effects of 
paracetamol.  The studies described here differ from previous studies in both mouse 
strain and the temperature of the thermal stimulus (55oC here, 52oC in the experiments 
reported by Abo Salem et al (2004)), factors that could underlie the difference in the 
observed effects of caffeine (Wilson and Mogil, 2001).  We used the higher 
temperature to ensure a supraspinal component to this antinociceptive test.  This 
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emphasises the importance of the experimental model, and suggests that the effects of 
caffeine may be highly dependent on the nature of the nociceptive stimulus. 
SCH58261 is a specific antagonist of the adenosine A2A receptor (Zocchi et al., 1996) 
that has been shown to have antinociceptive effects in CD1 mice in the hot plate test 
(52°C), but only when administered intrathecally, and not when administered i.p. 
(Bastia et al., 2002).  However in the experiments reported here SCH58261 (3 mg/kg) 
administered i.p. produced antinociception in the hot plate test (55°C), and this 
difference again may reflect the temperature or the nociceptive end point used.  We 
chose paw licking rather than jumping, which has been suggested to be a more 
sensitive and reliable nociceptive response than jumping (Wilson and Mogil, 2001).  
We also observed antinociceptive effects of SCH58261 in the tail immersion test (53 
°C) when administered i.p.  The antinociceptive effect of the A2A antagonist, together 
with the hypoalgesia seen in the A2A receptor knockout mice both in this study and 
previously (Ledent et al., 1997; Bailey et al., 2002a) confirms a pronociceptive role 
for adenosine A2A receptors.  We did not observe any further effect of paracetamol, 
caffeine or combinations of the two in either test in the knockout mice, probably 
because the increased nociceptive threshold in the knockouts masked any effects of 
the drugs.  Similarly, paracetamol was not able to induce a further increase in 
response latency in the presence of SCH58261.   
 
PSB1115 is a specific antagonist with 180-fold selectivity for human adenosine A2B 
receptor compared to the rat adenosine A2A receptor, that has been suggested to be 
unlikely to penetrate into the central nervous system due to its polar nature (Hayallah 
et al., 2002).  Abo-Salem et al (2004) reported that  PSB1115 at 10 mg/kg did not 
produce significant antinociception by itself in the hot plate test, but significantly 
potentiated the effects of morphine, presumably by an action at peripheral A2B 
receptors.  We also found little or no antinociceptive effect of PSB1115 alone at 10 
mg/kg in either the hot plate or the tail immersion test.  It significantly potentiated the 
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effect of paracetamol in the hot plate test, as was seen with morphine (Abo-Salem et 
al., 2004), but in contrast, it abolished the response to paracetamol in the tail 
immersion test.  The tail immersion test is predominantly a spinal reflex while the hot 
plate test produces nociceptive responses predominantly mediated at higher centres, 
but the opposing effects of PSB1115 on paracetamol-induced antinociception in the 
two tests are unlikely to reflect opposing roles for A2B receptors at the spinal and 
supraspinal levels if this compound does not enter the central nervous system.  
Instead, it is more likely to reflect opposing effects of peripheral A2B receptors in the 
pain pathways activated by the two tests.  Irrespective of the mechanism, the effect of 
PSB1115, like that of SCH58261, on paracetamol-induced antinociception did not 
mimic the effect of caffeine.   
In conclusion, paracetamol is antinociceptive in both spinal and supraspinal tests and 
the co-administration of caffeine reduces the effect of paracetamol, suggesting that 
these thermal nociceptive tests in the mouse produce opposite effects for caffeine to 
what has been reported in man.  Furthermore, antinociceptive responses to 
paracetamol and caffeine were dissimilar to responses of paracetamol combined with 
either an A2A or an A2B antagonist, suggesting that caffeine does not act at these 
receptors to oppose paracetamol antinociception. However, the opposing effects of the 
A2B receptor antagonist, PSB1115, on paracetamol-induced antinociception alone in a 
spinal and supraspinal thermal test suggests that the A2B receptor may be involved in 
the mechanisms of action of paracetamol and that this effect is dependent on the pain 
pathways activated.   The hypoalgesic nature of the A2A  knockout mice, and the 
ability of the A2A  antagonist SCH58261 to induce an antinociceptive effect at least 
equal to that of paracetamol in both spinal and supraspinal tests, support the existence 
of pronociceptive A2A receptors in pain pathways and suggest that an A2A antagonist 
may be clinically effective as an analgesic drug.   
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Figure Legends 
 
Fig. 1.  Antinociceptive effects of paracetamol and the effect of caffeine in the tail 
immersion test in mice.  The mean nociceptive response latency (± S.E.M; control 
n=18, treated groups n=6) in the tail immersion test (53 ± 1°C) prior and subsequent 
to the administration of (A) paracetamol (10-200 mg/kg), (B) paracetamol (10-200 
mg/kg) + caffeine (10 mg/kg) and (C) dose response curve (at 30 min. time point) 
subsequent to the administration of paracetamol (10-200 mg/kg) ± caffeine (10 
mg/kg). PBS=phosphate buffered saline.  * Treatment vs PBS; # Paracetamol plus 
caffeine vs paracetamol alone (P<0.05, ANOVA, Scheffe’s post hoc test).  
 
Fig. 2.  The effect of SCH58261 and PSB1115 alone and in the presence of 
paracetamol in the tail immersion test in mice.  The mean nociceptive response 
latency (± S.E.M; control n= 6-9, treated groups n=6) in the tail immersion test (55 ± 
1°C) prior and subsequent to the administration of paracetamol (50 mg/kg) ± A2 
antagonists; (A) SCH58261 (3 mg/kg) and (B) PSB1115 (10 mg/kg). PBS= phosphate 
buffered saline. * Treatment vs PBS. (P<0.05, ANOVA, Scheffe’s or Fischer LSD 
post hoc tests). 
 
Fig. 3. Antinociceptive effects of paracetamol and the effect of caffeine in the hot 
plate test in mice.  The mean nociceptive response latency (± S.E.M; control n=18, 
treated groups n=6) in the hotplate test (55 ± 1°C) prior and subsequent to the 
administration of (A) paracetamol (10-200 mg/kg), (B) paracetamol (50-200 mg/kg) + 
caffeine (10 mg/kg) and (C) dose response curve (at 30 min. time point) subsequent to 
the administration of paracetamol (10- 200 mg/kg) ± caffeine (10 mg/kg). 
PBS=phosphate buffered saline.  * Treatment vs PBS; # Paracetamol plus caffeine vs 
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paracetamol alone (P<0.05, ANOVA, Scheffe’s post hoc test). 
 
Fig.4.  The effect of  SCH58261 and PSB1115 alone and in the presence of 
paracetamol in the hotplate test in mice.  The mean nociceptive response latency (± 
S.E.M; control n= 6-9, treated groups n=6) in the hotplate test (55 ± 1°C) prior and 
subsequent to the administration of paracetamol (50 mg/kg) ± A2 antagonists; (A) 
SCH58261 (3 mg/kg) and (B) PSB1115 (10 mg/kg).  PBS= phosphate buffered saline. 
* Treatment vs PBS; # PSB1115 + paracetamol vs PSB1115 or paracetamol alone 
(P<0.05, ANOVA, Scheffe’s or Fischer LSD post hoc tests). 
